Press Releases

REDWOOD CITY, Calif. , Oct. 12, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal

REDWOOD CITY, Calif. , Oct. 11, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the issuance of a new patent (9,782,416) from the U.S.

Previously approved reverse stock split to be implemented on Friday, October 6, 2017 REDWOOD CITY, Calif. , Oct. 05, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today

REDWOOD CITY, Calif. , Sept. 25, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has received scientific advice  from the Committee for Medicinal

Updated Data Highlighted in Poster Presentation at 10 th International Meeting of Pediatric Endocrinology Phase III Study Expected to Begin by End of 2017 REDWOOD CITY, Calif. , Sept. 15, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company

Protection of Associated Claims into 2035 REDWOOD CITY, Calif. , Sept. 13, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the issuance of a new patent

David O’Toole to Depart Company ; Interim CFO Appointed and Search for New CFO Initiated REDWOOD CITY, Calif. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,

Completed Successful FDA Meeting for DCCR in Prader-Willi Syndrome Preparing to begin Phase III program by the end of the year Monetized Non-Strategic Assets Through Sale of NeoForce, Inc. Subsidiary REDWOOD CITY, Calif. , Aug. 11, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc.

REDWOOD CITY, Calif. , July 24, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the sale of one of its non-strategic subsidiaries, NeoForce, Inc.

Positive guidance received on key elements of Phase III program Company expects to initiate pivotal Phase III clinical trial by year-end 2017 DCCR has orphan designation for the treatment of PWS in the US REDWOOD CITY, Calif. , July 05, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc.